SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study
Authors:
- Alessandra MangiaAlessandra Mangia
- Giovanni CenderelloGCGiovanni Cenderello
- Massimiliano CopettiMCMassimiliano Copetti
- Gabriella VerucchiGVGabriella Verucchi
- Valeria PiazzollaVPValeria Piazzolla
- Celeste LorussoCLCeleste Lorusso
- Rosanna SantoroRSRosanna Santoro
- Maria Maddalena SquillanteMSMaria Maddalena Squillante
- Alessandra OrlandiniAOAlessandra Orlandini
- Rosalba MinisiniRMRosalba Minisini
- Alessia CiancioACAlessia Ciancio
Open Access
Abstract
In clinical trials, a sofosbuvir/velpatasvir (SOF/VEL) pangenotypic single-tablet regimen was associated with high sustained virological response (SVR) rates at 12 weeks (SVR12) after the end of treatment, regardless of genotype and fibrosis stage. No real-life data on genotype 3 (GT3) cirrhotic patients with portal hypertension are available. The aim of this study was to assess the effectiveness of SOF/VEL in GT3 cirrhotics with portal hypertension. Patients with GT3 and advanced cirrhosis were treated for 12 weeks with SOF/VEL without ribavirin at five different centers in Italy from June 2017 to August 2018 and their SVR12 was assessed. Of the 227 GT3 cirrhotics evaluated, 205 met the inclusion criteria and 111 had transient elastography results ≥20 KPa. SVR12 was 97.6% (95% CI 94.4–98.9), rates were 99.1% (95% CI 95.7–99.8) in patients with ≥20 KPa and 95.8% (95% CI 89.5–98.3) in those with p = 0.18). Analyzed by presence of esophageal varices, the SVR12 rates were 98.4% (95% CI 91.4–99.7) and 97.1% (95% CI 92.9–98.9) in patients without and with varices, respectively (p = 1.0). In real life, SOF/VEL GT3 cirrhotic patients with evidence of portal hypertension can achieve SVR12 levels comparable to those of patients without portal hypertension. These SVR12 rates are similar to what is reported in compensated cirrhosis treated within clinical trials.Keywords
This publication has 21 references indexed in Scilit:
- Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infectionJournal of Hepatology, 2018
- Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosisPLOS ONE, 2018
- High SVR rates in patients with and without cirrhosis treated in real life with Sofosbuvir/Velpatasvir (SOF/VEL) combination for 12 weeks without Ribavirin (RBV)Journal of Hepatology, 2018
- High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance‐associated substitutions in hepatitis C genotype 3 infectionAlimentary Pharmacology & Therapeutics, 2018
- Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated CirrhosisGastroenterology, 2017
- Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized TrialsGastroenterology, 2017
- Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 InfectionNew England Journal of Medicine, 2015
- Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated CirrhosisNew England Journal of Medicine, 2015
- Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 InfectionNew England Journal of Medicine, 2015
- Revising consensus in portal hypertension: Report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertensionJournal of Hepatology, 2010